Irene Schmid1, Anne K Klenk2, Monika Sparber-Sauer3, Ewa Koscielniak3,4, Rebecca Maxwell5, Beate Häberle5. 1. Division of Pediatric Hematology and Oncology, Dr. von Hauner Children's Hospital, Ludwig-Maximilians University of Munich, LMU, Lindwurmstr. 4, 80337, Munich, Germany. irene.schmid@med.uni-muenchen.de. 2. Division of Pediatric Hematology and Oncology, Dr. von Hauner Children's Hospital, Ludwig-Maximilians University of Munich, LMU, Lindwurmstr. 4, 80337, Munich, Germany. 3. Klinikum Stuttgart-Olgahospital, Stuttgart Cancer Center, Zentrum für Kinder-, Jugend- und Frauenmedizin, Pediatrics 5 (Oncology, Hematology, Immunology), Stuttgart, Germany. 4. Department of Pediatric Hematology and Oncology, Children's Hospital, Tübingen, Germany. 5. Pediatric Surgery, Dr. von Hauner Childen's Hospital, Ludwig-Maximilians University of Munich, Munich, Germany.
Abstract
BACKGROUND: Kaposiform hemangioendothelioma (KHE) is a rare vascular tumor affecting infants and young children. Although benign, it can be associated with an aggressive locally growing tumor and/or a life-threatening Kasabach-Merritt phenomenon (KMP). To date, only reviews of limited cases have been performed. We, therefore, conducted a comprehensive literature search to collect relevant data and make recommendations for future treatment trials. METHODS: Review of the available literature between 1993 and 2017 revealed a total of 105 publications involving 215 patients of less than 21 years of age. To this, we added 12 from our department and 4 from the Cooperative Weichteilsarkomstudie database. RESULTS: We found that KMP was present in 79% of the infants, in 47% of the 1-5-year olds, in 43% of the 6-12-year olds, and in 10% of the 13-21-year-old patients. KMP was present in nearly all (94%) patients with retroperitoneal tumors and in all patients with extra-regional tumors. The median size of a KHE without KMP was 12 cm2 as compared to 49 cm2 when associated with a KMP. With complete (not further classifiable if R0 or R1) resection, all patients were cured. If inoperable, response regarding KMP/regression of tumor size was seen in 29/28% with steroid-, 47/39% with vincristine-, 44/43% with interferon alpha-, 65/61% with anti-platelet agents-, and in 97/100% with sirolimus-containing therapies. CONCLUSIONS: Patients with progressive KHE should undergo resection whenever it is considered a safe option. If inoperable, sirolimus should be the first choice for treating KMP and reducing tumor size.
BACKGROUND: Kaposiform hemangioendothelioma (KHE) is a rare vascular tumor affecting infants and young children. Although benign, it can be associated with an aggressive locally growing tumor and/or a life-threatening Kasabach-Merritt phenomenon (KMP). To date, only reviews of limited cases have been performed. We, therefore, conducted a comprehensive literature search to collect relevant data and make recommendations for future treatment trials. METHODS: Review of the available literature between 1993 and 2017 revealed a total of 105 publications involving 215 patients of less than 21 years of age. To this, we added 12 from our department and 4 from the Cooperative Weichteilsarkomstudie database. RESULTS: We found that KMP was present in 79% of the infants, in 47% of the 1-5-year olds, in 43% of the 6-12-year olds, and in 10% of the 13-21-year-old patients. KMP was present in nearly all (94%) patients with retroperitoneal tumors and in all patients with extra-regional tumors. The median size of a KHE without KMP was 12 cm2 as compared to 49 cm2 when associated with a KMP. With complete (not further classifiable if R0 or R1) resection, all patients were cured. If inoperable, response regarding KMP/regression of tumor size was seen in 29/28% with steroid-, 47/39% with vincristine-, 44/43% with interferon alpha-, 65/61% with anti-platelet agents-, and in 97/100% with sirolimus-containing therapies. CONCLUSIONS:Patients with progressive KHE should undergo resection whenever it is considered a safe option. If inoperable, sirolimus should be the first choice for treating KMP and reducing tumor size.
Authors: Beth A Drolet; Cameron C Trenor; Leonardo R Brandão; Yvonne E Chiu; Robert H Chun; Roshni Dasgupta; Maria C Garzon; Adrienne M Hammill; Craig M Johnson; Brook Tlougan; Francine Blei; Michèle David; Ravindhra Elluru; Ilona J Frieden; Sheila F Friedlander; Ionela Iacobas; John N Jensen; David M King; Margaret T Lee; Stephen Nelson; Manish Patel; Elena Pope; Julie Powell; Marcia Seefeldt; Dawn H Siegel; Michael Kelly; Denise M Adams Journal: J Pediatr Date: 2013-07 Impact factor: 4.406
Authors: Brook E Tlougan; Margaret T Lee; Beth A Drolet; Ilona J Frieden; Denise M Adams; Maria C Garzon Journal: J Pediatr Hematol Oncol Date: 2013-11 Impact factor: 1.289
Authors: Adrienne M Hammill; MarySue Wentzel; Anita Gupta; Stephen Nelson; Anne Lucky; Ravi Elluru; Roshni Dasgupta; Richard G Azizkhan; Denise M Adams Journal: Pediatr Blood Cancer Date: 2011-03-28 Impact factor: 3.167
Authors: Alla Gruman; Marilyn G Liang; John B Mulliken; Steven J Fishman; Patricia E Burrows; Harry P W Kozakewich; Francine Blei; Ilona J Frieden Journal: J Am Acad Dermatol Date: 2005-04 Impact factor: 11.527
Authors: C F Barlow; C J Priebe; J B Mulliken; P D Barnes; D Mac Donald; J Folkman; R A Ezekowitz Journal: J Pediatr Date: 1998-03 Impact factor: 4.406
Authors: Thayná M de Lima Morais; Celeste Sánchez-Romero; Luciano Ribeiro; Daniele S Faé; Francielle S Verner; Oslei P de Almeida; Sibele Nascimento de Aquino Journal: Head Neck Pathol Date: 2021-03-13